Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma

Pediatric Surgery International

Volumn 23, Issue 5, 2007, Pages 431-439

  Seitz, Guido ^a   Warmann, Steven W ^a   Vokuhl, Christian O ^b   Heitmann, Heike ^a   Treuner, Claudia ^a   Leuschner, Ivo ^b   Fuchs, Jörg ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Multidrug resistance; Rhabdomyosarcoma; Xenograft

Indexed keywords

CALGRANULIN; CARBOPLATIN; DACTINOMYCIN; HYCAMPTIN; IFO CELL; IFOSFAMIDE; MESNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN MDM2; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER COMBINATION CHEMOTHERAPY; CELL LINE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; GENE CONTROL; HISTOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; XENOTRANSPLANTATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; SOFT TISSUE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34247201621     PISSN: 01790358     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00383-006-1852-z     Document Type: Conference Paper

References (43)

1. Fuchs J, Wenderoth M, von Schweinitz D, Haindl J, Leuschner I (1998) Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 83(11):2400-2407
2. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219-244
3. Cocker HA, Pinkerton CR, Kelland LR (2000) Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br J Cancer 83(3):338-345
4. Christ WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS (2001) Intergroup rhabdomyosarcoma study-IV: results of patients with non-metastatic disease. J Clin Oncol 19:3091-3102
5. Newton WA Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Tsokos MG, Shimada H, Harms D, Schmidt D (1995) Classification of rhabdomyosarcomas and related sarcomas. Cancer 76:1073-1085
6. Lawrence W Jr, Anderson JR, Gehan EA, Maurer H (1997) Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma study group. Children's cancer study group. Pediatric oncology group. Cancer 80:1165-1170
7. Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruyman F, Webber B, Hays DM, Wharam M, Maurer HM (1990) Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II intergroup rhabdomyosarcoma committee. J Clin Oncol 8:443-452
8. Treuner J, Koscielniak E (2003) Cooperative Weichteilsarkomstudie CWS 2002-P. Study protocol
9. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flammant F, Habrand JL, Marsden HB, Martelli H, Sanchez de Toledo J, Spicer RD, Spooner D, Terrier-Lacombe MJ, van Unnik A, Oberlin O (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the international society of paediatric oncology-SIOP malignant mesenchymal tumor 89. J Clin Oncol 23(12):2586-2587
10. Meza JL, Anderson J, Pappo AS, Meyer WH, Children's oncology group (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the children's oncology group. J Clin Oncol 24(24):3844-3851
11. Ferrari A, Casanova M, Bisogno G, Zanetti I, Cecchetto G, De Bernardi B, Riccardi R, Tamaro P, Meazza C, Alaggio R, Ninfo V, Carli M, Italian Cooperative Group (2003) Rhabdomyosarcoma in infants younger than one year old: a report from the italian cooperative group. Cancer 97(10):2597-2604
12. Warmann SW, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J (2002) The role of MDR1 gene in the development of multidrug resistance in human hepatoblastoma. Cancer 95(8):1795-1801
13. Chan HSL, Thorner PS, Haddad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein - prognostic correlation in soft-tissue sarcoma of the childhood. J Clin Oncol 8:689-704
14. De Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, Vielh P, Michon J (2006) Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer DOI 10.1002/pbc.20853
15. Ramachandran C, Melnick SJ, Escalon E, Jhabvala P, Khatib Z, Alamo A, Smith S (2000) Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric wilms' tumors. Anticancer Res 20(5C):3759-3765
16. △△C method. Methods 25:402-408
17. Singer S, Demetri GD, Baldini EH, Fletcher CD (2000) Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 1:75-85
18. Hoffmann J, Schmidt-Peter P, Hänsch W, Naundorf H, Bunge A, Becker M, Fichtner I (1999) Anticancer drug sensitivity and expression of multidrug resistance markers in early passage of human sarcomas. Clin Cancer Res 90(7):788-793
19. Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, Faircloth G, Jose J, D'Incalci M, Riccardi R (2003) Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 52:131-138
20. Thompson J, George O, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF, Houghton P (1999) Synergy of topotecan in combination with vincristin for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5:3617-3631
21. Koscielniak E, Morgan M, Treuner J (2002) Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs 4(1):21-28
22. Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM (2001) Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. J Pediatr Hematol Oncol 23(4):215-220
23. Cocker HA, Tiffin N, Pritchard-Jones K, Ross Pinkerton C, Kelland LR (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 7:3193-3198
24. Leuschner I, Heuer T, Harms D (2002) Induction of drug resistance in human rhabdomyosarcoma cell lines is associated with increased maturation: possible explanation for differentiation in recurrences? Pediatr Dev Pathol 5(3):276-282
25. Prados J, Melguizo C, Fernandez A, Aranega AE, Alvarez L, Aranega A (1996) Inverse expression of MDR1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin D. J Pathol 180(1):85-89
26. Cowie FJ, Pritchard-Jones K, Renshaw J, Pinkerton CR (1998) Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int J Oncol 12:1143-1149
27. Komdeur R, Klunder J, van der Graaf WT, van der Berg E, de Bont ES, Hoekstra HJ, Molenaar WM (2003) Multidrug resistance proteins in rhabdomyosarcomas. Cancer 97(8):1999-2005
28. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P (1993) Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein- mediated multidrug resistance. Cancer Res 53:1475-1479
29. Klunder JW, Komdeur R, Van der Graaf WT, De Bont EJ, Hoekstra HJ, Van der Berg E, Molenaar WM (2003) Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: the relationship between lung resistance-related protein (LRP) and differentiation. Hum Pathol 34(2):150-155
30. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC (2000) P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 35:96-103
31. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J (2001) Stabilization of MDM2 oncoprotein by mutant p53. J Biol Chem 276:6874-6878 32. Cocker HA, Hobbs SM, Tiffin N, Pinkerton CR, Kelland LR (2001) High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 85(11):1746-1752
32. Ruymann FB, Grovas AC (2000) Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest 18(3):223-241
33. Harms D (1995) Soft tissue sarcoma in the kiel pediatric tumor registry. In: Harms D, Schmidt D (eds) Current topics in pathology, soft tissue tumors, vol 89. Springer, Berlin Heidelberg New York, pp 31-45
34. Melguizo C, Prados J, Fernandez JE, Velez C, Alvarez L, Aranega A (1994) Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line. Cell Mol Biol 40(2):137-145
35. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51(5):1417-1423
36. Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M, Rosolen A (2005) Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 27(3):791-798
37. Warmann SW, Heitmann H, Teichmann B, Gratz KF, Ruck P, Hunger M, Fuchs J (2005) Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol 22(5):373-386
38. Warmann S, Gohring S, Teichmann B, Geerlings H, Pietsch T, Fuchs J (2003) P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 23(6C):4607-4611
39. Germann UA, Shlyakther D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer; reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140
40. Ganjavi H, Gee M, Narendan A, Freedman MH, Malkin D (2005) Adenovirus-mediated p53 gene therapy in pediatric soft tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther 12(4):397-406
41. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Nev M, Crepaldi T, Ponzetto C (2006) Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcomas. Cancer Res 66(9):4742-4749
42. Wu H, Hait WN, Yang JM (2003) Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63(7):1515-1519
43. Lage H (2006) MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7(7):813-821